Microvascular Therapeutics: Funding, Investors & Team (Oct 2026)
Microvascular Therapeutics has invented MVT-100, a novel ultrasound contrast agent with a patented design. This agent's neutral surface chemistry renders it suitable for the creation of molecular imaging agents and image-guided therapy. With its neutral surface chemistry, Microvascular Therapeutics-100 has the potential to be utilized in the development of molecular imaging agents and image-guided therapy. The company has also devised an expedited path for development, which could ultimately result in the approval of MVT-100 specifically for echocardiography purposes.
Microvascular Therapeutics has raised $4.0M across 3 funding rounds on record, the most recent an undisclosed round of $4.0M announced in Oct 2023.
That round is below the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Microvascular Therapeutics Company Profile and Key Stats
Latest funding round on record: Oct 2023.
Microvascular Therapeutics Funding Rounds
2 of 3 rounds were announced without a disclosed amount and are excluded from the total.
Microvascular Therapeutics announced a Grant in Apr 2022; the amount was not disclosed.
7 months later, an undisclosed round was announced in Nov 2022 with no disclosed amount.
11 months later, an undisclosed round of $4.0M was announced in Oct 2023.
Microvascular Therapeutics Founders and Leadership Team
No contact details are on record for this team yet.
Microvascular Therapeutics Funding Compared to Other Biotechnology Startups
Microvascular Therapeutics' latest round of $4.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Microvascular Therapeutics in Biotechnology and Tucson
Companies Similar to Microvascular Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
Microvascular Therapeutics Funding FAQs
What does Microvascular Therapeutics do?
Microvascular Therapeutics has invented MVT-100, a novel ultrasound contrast agent with a patented design. This agent's neutral surface chemistry renders it suitable for the creation of molecular imaging agents and image-guided therapy. With its neutral surface chemistry, Microvascular Therapeutics-100 has the potential to be utilized in the development of molecular imaging agents and image-guided therapy. The company has also devised an expedited path for development, which could ultimately result in the approval of MVT-100 specifically for echocardiography purposes.
How much funding has Microvascular Therapeutics raised?
Microvascular Therapeutics has raised $4.0M across 3 rounds on record. The most recent is an undisclosed round of $4.0M announced in Oct 2023.
When did Microvascular Therapeutics last raise funding?
Microvascular Therapeutics' most recent funding round on record is an undisclosed round of $4.0M, announced in Oct 2023.
Who is the CEO of Microvascular Therapeutics?
Evan C Unger is listed as CEO at Microvascular Therapeutics.
Where is Microvascular Therapeutics headquartered?
Microvascular Therapeutics is based in Tucson, Arizona, United States.
How many employees does Microvascular Therapeutics have?
Microvascular Therapeutics is in the 1-10 employee band.
How does Microvascular Therapeutics' funding compare to other Biotechnology startups?
Microvascular Therapeutics' latest round of $4.0M is below the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Microvascular Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Microvascular Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.